These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 24409449)

  • 1. Immune heterogeneity of glioblastoma subtypes: extrapolation from the cancer genome atlas.
    Doucette T; Rao G; Rao A; Shen L; Aldape K; Wei J; Dziurzynski K; Gilbert M; Heimberger AB
    Cancer Immunol Res; 2013 Aug; 1(2):112-22. PubMed ID: 24409449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glioblastoma TCGA Mesenchymal and IGS 23 Tumors are Identifiable by IHC and have an Immune-phenotype Indicating a Potential Benefit from Immunotherapy.
    Carrato C; Alameda F; Esteve-Codina A; Pineda E; Arpí O; Martinez-García M; Mallo M; Gut M; Lopez-Martos R; Barco SD; Ribalta T; Capellades J; Puig J; Gallego O; Mesia C; Muñoz-Marmol AM; Archilla I; Arumí M; Blanc JM; Bellosillo B; Menendez S; Esteve A; Bagué S; Hernandez A; Craven-Bartle J; Fuentes R; Vidal N; Aldecoa I; Iglesia N; Balana C
    Clin Cancer Res; 2020 Dec; 26(24):6600-6609. PubMed ID: 32998960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Unique genome-wide map of TCF4 and STAT3 targets using ChIP-seq reveals their association with new molecular subtypes of glioblastoma.
    Zhang JX; Zhang J; Yan W; Wang YY; Han L; Yue X; Liu N; You YP; Jiang T; Pu PY; Kang CS
    Neuro Oncol; 2013 Mar; 15(3):279-89. PubMed ID: 23295773
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
    Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
    Front Immunol; 2022; 13():773264. PubMed ID: 35185876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesenchymal and Proneural Subtypes of Glioblastoma Disclose Branching Based on GSC Associated Signature.
    Steponaitis G; Tamasauskas A
    Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34066996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioinformatic analyses reveal a distinct Notch activation induced by STAT3 phosphorylation in the mesenchymal subtype of glioblastoma.
    Cheng W; Zhang C; Ren X; Jiang Y; Han S; Liu Y; Cai J; Li M; Wang K; Liu Y; Hu H; Li Q; Yang P; Bao Z; Wu A
    J Neurosurg; 2017 Jan; 126(1):249-259. PubMed ID: 26967788
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Systematic identification, development, and validation of prognostic biomarkers involving the tumor-immune microenvironment for glioblastoma.
    Zhao B; Wang Y; Wang Y; Chen W; Liu PH; Kong Z; Dai C; Wang Y; Ma W
    J Cell Physiol; 2021 Jan; 236(1):507-522. PubMed ID: 32572951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic estimates of aneuploid content in glioblastoma multiforme and improved classification.
    Li B; Senbabaoglu Y; Peng W; Yang ML; Xu J; Li JZ
    Clin Cancer Res; 2012 Oct; 18(20):5595-605. PubMed ID: 22912392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Coexpression analysis of CD133 and CD44 identifies proneural and mesenchymal subtypes of glioblastoma multiforme.
    Brown DV; Daniel PM; D'Abaco GM; Gogos A; Ng W; Morokoff AP; Mantamadiotis T
    Oncotarget; 2015 Mar; 6(8):6267-80. PubMed ID: 25749043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subtype-specific signaling pathways and genomic aberrations associated with prognosis of glioblastoma.
    Park AK; Kim P; Ballester LY; Esquenazi Y; Zhao Z
    Neuro Oncol; 2019 Jan; 21(1):59-70. PubMed ID: 30053126
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptome analyses reveal molecular mechanisms underlying phenotypic differences among transcriptional subtypes of glioblastoma.
    Pan YB; Wang S; Yang B; Jiang Z; Lenahan C; Wang J; Zhang J; Shao A
    J Cell Mol Med; 2020 Apr; 24(7):3901-3916. PubMed ID: 32091665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved prognostication of glioblastoma beyond molecular subtyping by transcriptional profiling of the tumor microenvironment.
    Jeanmougin M; Håvik AB; Cekaite L; Brandal P; Sveen A; Meling TR; Ågesen TH; Scheie D; Heim S; Lothe RA; Lind GE
    Mol Oncol; 2020 May; 14(5):1016-1027. PubMed ID: 32171051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The landscape of the mesenchymal signature in brain tumours.
    Behnan J; Finocchiaro G; Hanna G
    Brain; 2019 Apr; 142(4):847-866. PubMed ID: 30946477
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MRI-localized biopsies reveal subtype-specific differences in molecular and cellular composition at the margins of glioblastoma.
    Gill BJ; Pisapia DJ; Malone HR; Goldstein H; Lei L; Sonabend A; Yun J; Samanamud J; Sims JS; Banu M; Dovas A; Teich AF; Sheth SA; McKhann GM; Sisti MB; Bruce JN; Sims PA; Canoll P
    Proc Natl Acad Sci U S A; 2014 Aug; 111(34):12550-5. PubMed ID: 25114226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
    Ma S; Ba Y; Ji H; Wang F; Du J; Hu S
    Front Immunol; 2021; 12():738435. PubMed ID: 34603319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Classification of Glioblastoma Associated with Immune Checkpoints and Tumor Microenvironment based on Immunogenomic Profiling.
    Zheng P; Zhang X; Ren D; Bai Q
    Neurol India; 2024 Mar; 72(2):297-303. PubMed ID: 38691473
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stem cell signature in glioblastoma: therapeutic development for a moving target.
    Nakano I
    J Neurosurg; 2015 Feb; 122(2):324-30. PubMed ID: 25397368
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular heterogeneity in a patient-derived glioblastoma xenoline is regulated by different cancer stem cell populations.
    Garner JM; Ellison DW; Finkelstein D; Ganguly D; Du Z; Sims M; Yang CH; Interiano RB; Davidoff AM; Pfeffer LM
    PLoS One; 2015; 10(5):e0125838. PubMed ID: 25955030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HOTAIR, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma.
    Zhang JX; Han L; Bao ZS; Wang YY; Chen LY; Yan W; Yu SZ; Pu PY; Liu N; You YP; Jiang T; Kang CS;
    Neuro Oncol; 2013 Dec; 15(12):1595-603. PubMed ID: 24203894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A three-microRNA signature identifies two subtypes of glioblastoma patients with different clinical outcomes.
    Marziali G; Buccarelli M; Giuliani A; Ilari R; Grande S; Palma A; D'Alessandris QG; Martini M; Biffoni M; Pallini R; Ricci-Vitiani L
    Mol Oncol; 2017 Sep; 11(9):1115-1129. PubMed ID: 28248456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.